Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT03485547
Phase
PHASE1
Status
Completed

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct

Study Details

This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax

Key Dates

Start date
Aug 23, 2018
Status verified
Jan 2026
Primary completion
Jan 10, 2022
Completion
Apr 16, 2025

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Venetoclax
    * Venetoclax is administered on a daily basis orally. * The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax.

Primary Outcome Measure

Dose Limiting Toxicity [ Time Frame: 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Boston, MA

By research site
Dana Farber Cancer Institute· Boston, MAMD Anderson Cancer Center· Houston, TX

Related Studies